TNGX — Tango Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819133 ·
Last close
$31.06
Market Cap
$5.06B
52W High
$34.39
52W Low
$19.34
ADV30
5,463,775
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -48,769,000 | -45,514,000 | 435,792,000 | 157,828,000 | 44,286,000 |
| Dec 2025 | 0 | — | -41,864,000 | -38,749,000 | 398,690,000 | 112,279,000 | 52,511,000 |
| Sep 2025 | 53,811,000 | — | 14,072,000 | 15,884,000 | 210,136,000 | 58,338,000 | 50,105,000 |
| Jun 2025 | 3,181,000 | — | -40,967,000 | -38,853,000 | 237,890,000 | 39,272,000 | 102,936,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-141,549,000
Investing CF
$-61,827,000
Financing CF
$302,344,000
CapEx
$-1,048,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-648,666,000
Inventory
—
Receivables
—
ST Investments
$222,011,000
EBIT TTM
$-117,528,000
Pretax Income TTM
$-107,261,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$56,992,000
EBITDA
$-115,406,000
Free Cash Flow
$-68,235,000
Enterprise Value
$4,067,605,504
Total Cash
$379,839,008
Total Debt
$32,788,000
Shares Out
162,814,649
Trailing EPS
$-0.83
Book Value
$2.72
ROE
-38.4%
ROA
-20.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,384,000 | -111,289,000 | -101,594,000 | 398,690,000 | 52,511,000 | — | -138,886,000 |
| Dec 2024 | 42,069,000 | -145,595,000 | -130,302,000 | 316,492,000 | 116,975,000 | — | -131,501,000 |
| Dec 2023 | 36,527,000 | -114,173,000 | -101,744,000 | 402,567,000 | 149,459,000 | — | -117,982,000 |
| Dec 2022 | 24,860,000 | -111,071,000 | -108,176,000 | 436,470,000 | 186,994,000 | — | -109,080,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MANE | Veradermics, Inc | $5.00B | $119.60 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.89B | $45.41 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.23B | $86.79 | — |
| LEGN | Legend Biotech Corp | $5.24B | $27.08 | — |
| TVTX | Travere Therapeutics, Inc. | $5.26B | $56.59 | — |
News headlines (Yahoo Finance, 1h cache)
2 Monster Growth Stocks Analysts Think Can Reach New Highs
2026-07-09 17:54 · Yahoo
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
2026-07-02 14:50 · Yahoo
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
2026-07-02 14:46 · Yahoo
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
2026-07-02 14:43 · Yahoo
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
2026-06-26 19:38 · Yahoo
Tango Therapeutics Appoints Robert Azelby to Board of Directors
2026-06-22 20:05 · Yahoo
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
2026-06-12 00:23 · Yahoo
Is Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One Year
2026-06-10 08:10 · Yahoo
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
2026-06-10 02:49 · Yahoo
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
2026-06-09 16:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.